Literature DB >> 14982881

The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT.

Shinichiro Takahashi1, Melanie J McConnell, Hideo Harigae, Mitsuo Kaku, Takeshi Sasaki, Ari M Melnick, Jonathan D Licht.   

Abstract

Fms-like tyrosine kinase 3 (Flt3) is a type III receptor tyrosine kinase (RTK). Between 20% and 30% of acute myeloid leukemia (AML) patients have either an internal tandem duplication (ITD) of the juxtamembrane region or a point mutation of the Flt3 receptor leading to the constitutive activation of downstream signaling pathways and aberrant cell growth. The silencing mediator of retinoic and thyroid hormone receptors (SMRT) corepressor mediates transcriptional repression by interacting with transcription factors such as the promyelocytic leukemia zinc finger (PLZF) protein. Previous reports indicate that SMRT interaction with transcription factors can be disrupted by phosphorylation through activation of RTK pathways. We report here that the Flt3-ITD interferes with the transcriptional and biologic action of the PLZF transcriptional repressor. In the presence of Flt3-ITD, PLZF-SMRT interaction was reduced, transcriptional repression by PLZF was inhibited, and PLZF-mediated growth suppression of leukemia cells was partially blocked. Furthermore, overexpression of Flt3-ITD led to a partial relocalization of SMRT protein from the nucleus to the cytoplasm. Nuclear export was dependent on the SMRT receptor interaction domain (RID), and Flt3-ITD enhances the binding of nuclear-cytoplasm shuttling protein nuclear factor-kappaB-p65 (NFkappaB-p65) to this region. These data suggest that activating mutations of Flt3 may disrupt transcriptional repressor function resulting in aberrant gene regulation and abnormal leukemia cell growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982881     DOI: 10.1182/blood-2003-08-2759

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Fusion-protein truncation provides new insights into leukemogenesis.

Authors:  Jay L Hess; Bruce A Hug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-30       Impact factor: 11.205

2.  Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells.

Authors:  Jose M Polo; Weimin Ci; Jonathan D Licht; Ari Melnick
Journal:  Blood       Date:  2008-05-16       Impact factor: 22.113

3.  Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.

Authors:  Shinichiro Takahashi; Hideo Harigae; Hisayuki Yokoyama; Izumi Ishikawa; Shouri Abe; Masue Imaizumi; Takeshi Sasaki; Mitsuo Kaku
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

4.  Internal tandem duplication and tyrosine kinase domain mutations in FLT3 alter the response to daunorubicin in Ba/F3 cells.

Authors:  Shinichiro Takahashi; Kumi Shirahama
Journal:  Biomed Rep       Date:  2015-11-09

5.  Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells.

Authors:  Akemi Imoto; Mami Okada; Toshio Okazaki; Hidero Kitasato; Hideo Harigae; Shinichiro Takahashi
Journal:  J Biol Chem       Date:  2010-02-05       Impact factor: 5.157

Review 6.  Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.

Authors:  Luke F Peterson; Anita Boyapati; Eun-Young Ahn; Joseph R Biggs; Akiko Joo Okumura; Miao-Chia Lo; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

7.  PLZF is a regulator of homeostatic and cytokine-induced myeloid development.

Authors:  Sergei Doulatov; Faiyaz Notta; Kim L Rice; Louise Howell; Arthur Zelent; Jonathan D Licht; John E Dick
Journal:  Genes Dev       Date:  2009-09-01       Impact factor: 11.361

Review 8.  Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.

Authors:  Shinichiro Takahashi
Journal:  J Hematol Oncol       Date:  2011-04-01       Impact factor: 17.388

9.  The promyelocytic leukemia zinc finger protein: two decades of molecular oncology.

Authors:  Bandar Ali Suliman; Dakang Xu; Bryan Raymond George Williams
Journal:  Front Oncol       Date:  2012-07-17       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.